New pill aims to tame fibroid bleeding without surgery
NCT ID NCT07319520
First seen Jan 11, 2026 · Last updated Jun 22, 2026 · Updated 17 times
Summary
This Phase 2 trial tested an oral drug called DW4902 in 71 premenopausal women with uterine fibroids and heavy menstrual bleeding. Participants took either a placebo or one of three doses of DW4902 daily for 12 weeks. The main goal was to see if the drug could reduce bleeding to near-normal levels, offering a potential alternative to surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOMA OF UTERUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, South Korea
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DW4902 (an oral drug)
What this could lead to
If it works, this could provide a new non-surgical option to ease heavy bleeding caused by uterine fibroids.
What could go wrong
This is an early Phase 2 trial with only 71 people, so results may not hold up in larger studies. The drug may cause side effects or fail to improve symptoms significantly.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.